Rare disease levels of evidence: Time for a new bar?

Affiliations

¹ From The Ellen and Martin Prosserman Centre for Neuromuscular Diseases (V.B.), University Health Network, University of Toronto, Canada; and Department of Neurology (H.J.K.), George Washington University, Washington, DC. Vera.bril@utoronto.ca.
² From The Ellen and Martin Prosserman Centre for Neuromuscular Diseases (V.B.), University Health Network, University of Toronto, Canada; and Department of Neurology (H.J.K.), George Washington University, Washington, DC.

Editorial

Vera Bril et al. Neurology. 2017.

. 2017 Sep 5;89(10):988-989.

doi: 10.1212/WNL.0000000000004343. Epub 2017 Aug 11.

¹ From The Ellen and Martin Prosserman Centre for Neuromuscular Diseases (V.B.), University Health Network, University of Toronto, Canada; and Department of Neurology (H.J.K.), George Washington University, Washington, DC. Vera.bril@utoronto.ca.
² From The Ellen and Martin Prosserman Centre for Neuromuscular Diseases (V.B.), University Health Network, University of Toronto, Canada; and Department of Neurology (H.J.K.), George Washington University, Washington, DC.

No abstract available

Comment on

Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF Jr, Howard D, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, LaBoy SM, Fellman MA, Greene SM, Pasnoor M, Burns TM. Hehir MK, et al. Neurology. 2017 Sep 5;89(10):1069-1077. doi: 10.1212/WNL.0000000000004341. Epub 2017 Aug 11. Neurology. 2017. PMID: 28801338